EP
IRMD icon

Essential Partners’s iRadimed IRMD Stock Holding History

Essential Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Hold
41
– – ﹤0.01% 1651
2026
Q1 		$3.95K Hold
41
– – ﹤0.01% 1695
2025
Q4 		$3.99K Buy
41
+3
+8% +$257 ﹤0.01% 1526
2025
Q3 		$2.7K Buy
38
+20
+111% +$1.33K ﹤0.01% 1689
2025
Q2 		$1.08K Buy
+18
New +$987 ﹤0.01% 1493

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's IRMD Position: Q2 2026 in Review

Essential Partners held its iRadimed (IRMD) position steady in Q2 2026 at 41 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

Essential Partners first reported a position in IRMD in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.99K in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Essential Partners held 41 shares of iRadimed worth $3.92K as of Q2 2026.
  • Essential Partners left its iRadimed share count unchanged in Q2 2026.
  • iRadimed made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1651 holding.
  • Essential Partners first reported a position in iRadimed in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's iRadimed position peaked at $3.99K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.